Generation of human vascularized and chambered cardiac organoids for cardiac disease modelling and drug evaluation

Abstract

Human induced pluripotent stem cell (hiPSC)-derived cardiac organoids (COs) have shown great potential in modelling human heart development and cardiovascular diseases, a leading cause of global death. However, several limitations such as low reproducibility, limited vascularization and difficulty in formation of cardiac chamber were yet to be overcome. We established a new method for robust generation of COs, via combination of methodologies of hiPSC-derived vascular spheres and directly differentiated cardiomyocytes from hiPSCs, and investigated the potential application of human COs in cardiac injury modelling and drug evaluation. The human COs we built displayed a vascularized and chamber-like structure, and hence were named vaschamcardioids (vcCOs). These vcCOs exhibited approximately 90% spontaneous beating ratio. Single-cell transcriptomics identified a total of six cell types in the vcCOs, including cardiomyocytes, cardiac precursor cells, endothelial cells, fibroblasts, etc. We successfully recaptured the processes of cardiac injury and fibrosis in vivo on vcCOs, and showed that the FDA-approved medication captopril significantly attenuated cardiac injury-induced fibrosis and functional disorders. In addition, the human vcCOs exhibited an obvious drug toxicity reaction to doxorubicin in a dose-dependent manner. We developed a three-step method for robust generation of chamber-like and vascularized complex vcCOs, and our data suggested that vcCOs might become a useful model for understanding pathophysiological mechanisms of cardiovascular diseases, developing intervention strategies and screening drugs.

References

[1] TsaoCW, AdayAW, AlmarzooqZI, et al. Heart disease and stroke Statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621.

[2] HayM, ThomasDW, CraigheadJL, Economides C, RosenthalJ. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51.

[3] SunD, GaoW, HuH, ZhouS. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12(7):3049-3062.

[4] ThomasD, ChoiS, AlamanaC, Parker KK, WuJC. Cellular and engineered organoids for cardiovascular models. Circ Res. 2022;130(12):1780-1802.

[5] YeL, YuY, ZhaoZA, et al. Patient-specific iPSC-derived cardiomyocytes reveal abnormal regulation of FGF16 in a familial atrial septal defect. Cardiovasc Res. 2022;118(3):859-871.

[6] NiX, YangZZ, YeLQ, et al. Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells. Acta Pharmacol Sin. 2022;43(1):240-250.

[7] LeeJ, Termglinchan V, DieckeS, et al. Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy. Nature. 2019;572(7769):335-340.

[8] SharmaA, McKeithan WL, SerranoR, et al. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity. Nat Protoc. 2018;13(12):3018-3041.

[9] GiacomelliE, Meraviglia V, CampostriniG, et al. Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease. Cell Stem Cell. 2020;26(6):862-879.

[10] Lewis-IsraeliYR, Wasserman AH, GabalskiMA, et al. Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease. Nat Commun. 2021;12(1):5142.

[11] ForsytheSD, Devarasetty M, ShupeT, et al. Environmental toxin screening using human-derived 3D bioengineered liver and cardiac organoids. Front Public Health. 2018;6:103.

[12] GiacomelliE, BellinM, SalaL, et al. Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells. Development. 2017;144(6):1008-1017.

[13] HoangP, WangJ, ConklinBR, Healy KE, MaZ. Generation of spatial-patterned early-developing cardiac organoids using human pluripotent stem cells. Nat Protoc. 2018;13(4):723-737.

[14] LeiW, FengT, FangX, et al. Signature of circular RNAs in human induced pluripotent stem cells and derived cardiomyocytes. Stem Cell Res Ther. 2018;9(1):56.

[15] WimmerRA, Leopoldi A, AichingerM, KerjaschkiD, Penninger JM. Generation of blood vessel organoids from human pluripotent stem cells. Nat Protoc. 2019;14(11):3082-3100.

[16] KimJ, KooBK, KnoblichJA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol. 2020;21(10):571-584.

[17] SchutgensF, Clevers H. Human organoids: tools for understanding biology and treating diseases. Annu Rev Pathol. 2020;15:211-234.

[18] TakasatoM, ErPX, ChiuHS, et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature. 2015;526(7574):564-568.

[19] SerraD, MayrU, BoniA, et al. Self-organization and symmetry breaking in intestinal organoid development. Nature. 2019;569(7754):66-72.

[20] MansourAA, Goncalves JT, BloydCW, et al. An in vivo model of functional and vascularized human brain organoids. Nat Biotechnol. 2018;36(5):432-441.

[21] DrakhlisL, Biswanath S, FarrCM, et al. Human heart-forming organoids recapitulate early heart and foregut development. Nat Biotechnol. 2021;39(6):737-746.

[22] HofbauerP, JahnelSM, PapaiN, et al. Cardioids reveal self-organizing principles of human cardiogenesis. Cell. 2021;184(12):3299-3317.

[23] HoBX, PangJKS, ChenY, et al. Robust generation of human-chambered cardiac organoids from pluripotent stem cells for improved modelling of cardiovascular diseases. Stem Cell Res Ther. 2022;13(1):529.

[24] RichardsDJ, LiY, KerrCM, et al. Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity. Nat Biomed Eng. 2020;4(4):446-462.

[25] ZhaoD, LeiW, HuS. Cardiac organoid -a promising perspective of preclinical model. Stem Cell Res Ther. 2021;12(1):272.

[26] WimmerRA, Leopoldi A, AichingerM, et al. Human blood vessel organoids as a model of diabetic vasculopathy. Nature. 2019;565(7740):505-510.

[27] LiuC, FengX, LiG, Gokulnath P, XiaoJ. Generating 3D human cardiac constructs from pluripotent stem cells. EBioMedicine. 2022;76:103813.

[28] ChoJ, LeeH, RahW, ChangHJ, YoonYS. From engineered heart tissue to cardiac organoid. Theranostics. 2022;12(6):2758-2772.

[29] LitvinukovaM, Talavera-Lopez C, MaatzH, et al. Cells of the adult human heart. Nature. 2020;588(7838):466-472.

[30] CuiY, ZhengY, LiuX, et al. Single-cell transcriptome analysis maps the developmental track of the human heart. Cell Rep. 2019;26(7):1934-1950.

[31] SuryawanshiH, ClancyR, MorozovP, Halushka MK, BuyonJP, TuschlT. Cell atlas of the foetal human heart and implications for autoimmune-mediated congenital heart block. Cardiovasc Res. 2020;116(8):1446-1457.

[32] DewingJM, Saunders V, O’KellyI, WilsonDI. Defining cardiac cell populations and relative cellular composition of the early fetal human heart. PloS One. 2022;17(11):e0259477.

[33] TuckerNR, Chaffin M, FlemingSJ, et al. Transcriptional and cellular diversity of the human heart. Circulation. 2020;142(5):466-482.

[34] WangL, YuP, ZhouB, et al. Single-cell reconstruction of the adult human heart during heart failure and recovery reveals the cellular landscape underlying cardiac function. Nat Cell Biol. 2020;22(1):108-119.

[35] AnR, ZhaoL, XiC, et al. Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism. Basic Res Cardiol. 2016;111(1):8.

[36] LinZ, ZhouP, von GiseA, et al. Pi3kcb links Hippo-YAP and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival. Circ Res. 2015;116(1):35-45.

[37] BekhiteMM, Finkensieper A, BinasS, et al. VEGF-mediated PI3K class IA and PKC signaling in cardiomyogenesis and vasculogenesis of mouse embryonic stem cells. J Cell Sci. 2011;124(Pt 11):1819-1830.

[38] ZhangQ, WangL, WangS, et al. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct Target Ther. 2022;7(1):78.

[39] FrangogiannisNG. The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest. 2017;127(5):1600-1612.

[40] FrangogiannisNG. The extracellular matrix in ischemic and nonischemic heart failure. Circ Res. 2019;125(1):117-146.

[41] SugdenPH. Ras, Akt, and Mechanotransduction in the cardiac myocyte. Circ Res. 2003;93(12):1179-1192.

[42] YuanS, Stewart KS, YangY, et al. Ras drives malignancy through stem cell crosstalk with the microenvironment. Nature. 2022;612(7940):555-563.

[43] VogesHK, FosterSR, ReynoldsL, et al. Vascular cells improve functionality of human cardiac organoids. Cell Rep. 2023;42(5):112322.

[44] MartinM, Gahwiler EKN, GeneraliM, HoerstrupSP, EmmertMY. Advances in 3D organoid models for stem cell-based cardiac regeneration. Int J Mol Sci. 2023;24(6):5188.

[45] CostaA, Cushman S, HaubnerBJ, DerdaAA, ThumT, BarC. Neonatal injury models: integral tools to decipher the molecular basis of cardiac regeneration. Basic Res Cardiol. 2022;117(1):26.

[46] ZhangY, ZhangL, FanX, et al. Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a/beta-catenin and Jak2/Stat3 pathways. Biomed Pharmacother. 2019;113:108780.

[47] SolomonSD, SkaliH, AnavekarNS, et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005;111(25):3411-3419.

[48] ForteE, Furtado MB, RosenthalN. The interstitium in cardiac repair: role of the immune-stromal cell interplay. Nat Rev Cardiol. 2018;15(10):601-616.

[49] VagnozziRJ, Maillet M, SargentMA, et al. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature. 2020;577(7790):405-409.

RIGHTS & PERMISSIONS

2024 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.